Solbec application

SOLBEC Pharmaceuticals Ltd has filed two new provisional patent applications with the Australian and US Patent Offices.

The filings cover intellectual property developed in respect of extraction, purification and optimal formulation of the company’s BEC-2S anti-cancer agent. Solbec is concluding contracts to acquire a 17-acre property south of Perth where it can grow the Devil’s Apple weed, the source of its BEC raw material.

The company has also commissioned Chem Eng Contracts Pty Ltd to provide conceptual design and order of magnitude costing for the BEC manufacturing facility to be established at its Osborne Park HQ.

Pass for Chemeq drug

PHARMACEUTICAL company Chemeq Ltd last week received South African regulatory approval for the porcine use of its polymeric antimicrobial drug.

Chemeq said its polymeric antimicrobial is an alternative to the use of human antibiotics in animals.

Regulatory approval processes for Chemeq’s drug are under way in the US, Europe, Australia, New Zealand and a number of Asian countries.